Skip to main content

Roger Gomis is awarded the "Valdés-Salas" Prize for Applied Biomedicine

Images

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

The jury, chaired by Carlos López-Otín, endorses the research on bone metastasis that led to the set up of the spin-off Inbiomotion.

The Asturian “Valdés-Salas” Foundation, chaired by the scientist Carlos López-Otín, has unanimously awarded the II Applied Biomedicine Prize to IRB Barcelona researcher Roger Gomis. Dr. Gomis heads the Growth Control and Cancer Metastasis group, part of the Oncology Programme, which identified a gene with the capacity to predict bone metastasis in breast cancer patients and which was the group from which the biotech enterprise Inbiomotion arose. The decision of the jury highlights that “the research by Dr. Gomis once again demonstrates that basic investigation of excellence can provide concrete and practical answers to problems of great biomedicine relevance”.

Founded by Roger Gomis in 2010 and located in the Barcelona Science Park, Inbiomotion seeks to develop an assay to validate a marker with the capacity to predict bone metastasis in cancer patients using a technology developed at IRB Barcelona. In 2012, the company received a 2-million euro investment from Ysios Capital, the Vila Casas Foundation and JVRisk Technologies.

In addition to López-Otín, the jury members were as follows: the dean of the University of Oviedo, Vicente Gotor; emeritus professor of CSIC, José Elguero; senior professor of Pharmacology, Agustín Delgado; senior professor of Microbiology, Evaristo Suárez; director of Advancell, Clara Compás-Moya; medical director of Bayer-Healthcare, Ramon Estiarte; president of the Cooperativa Farmacéutica Asturiana, Pablo Ramos; and the president of ILAS Reny-Picot, Francisco Rodríguez.

Link to Valdés-Salas Foundation

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).